Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of M72/AS01E-4 vaccine for prevention of pulmonary tuberculosis in adolescents and adults
PACTR202401850967550Phase 3Unknown
- Sponsor
- Gates Medical Research Institute
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Tuberculosis (TB) comparing M72/AS01E-4 vaccine with Placebo (2 arms). Primary endpoint: Number of participants with laboratory-confirmed pulmonary tuberculosis in the IGRA-positive cohort. Status: unknown.
02
Drugs
M72/AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202401850967550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202401850967550.